Anti-SLC35E4 monoclonal antibody

Pre-made anti-SLC35E4 monoclonal antibody(mab)-benchmark antibody for ELISA, affinity binding assay, drug discovery and mechanism of action (MOA) research

Target products collectionGo to SLC35E4/SLC35E4 products collection >>
(antibodies, antigen, VLP, mRNA, ORF viral vector, etc)

pdfMSDSpdfCOApdfDatasheet

Product information

Catalog No.Product NameSpecies Reactivity
GM-Tg-hg-IP1717-Ab-1/ GM-Tg-hg-IP1717-Ab-2Anti-Human SLC35E4 monoclonal antibodyHuman
GM-Tg-rg-IP1717-Ab-1/ GM-Tg-rg-IP1717-Ab-2Anti-Rat SLC35E4 monoclonal antibodyRat
GM-Tg-mg-IP1717-Ab-1/ GM-Tg-mg-IP1717-Ab-2Anti-Mouse SLC35E4 monoclonal antibodyMouse
GM-Tg-cynog-IP1717-Ab-1/ GM-Tg-cynog-IP1717-Ab-2Anti-Cynomolgus/ Rhesus macaque SLC35E4 monoclonal antibodyCynomolgus/ Rhesus macaque
GM-Tg-felg-IP1717-Ab-1/ GM-Tg-felg-IP1717-Ab-2Anti-Feline SLC35E4 monoclonal antibodyFeline
GM-Tg-cang-IP1717-Ab-1/ GM-Tg-cang-IP1717-Ab-2Anti-Canine SLC35E4 monoclonal antibodyCanine
GM-Tg-bovg-IP1717-Ab-1/ GM-Tg-bovg-IP1717-Ab-2Anti-Bovine SLC35E4 monoclonal antibodyBovine
GM-Tg-equg-IP1717-Ab-1/ GM-Tg-equg-IP1717-Ab-2Anti-Equine SLC35E4 monoclonal antibodyEquine

Size： 1mg | 10mg | 100mg



Product Description

Catalog No.GM-Tg-hg-IP1717-Ab-1/ GM-Tg-hg-IP1717-Ab-2; GM-Tg-rg-IP1717-Ab-1/ GM-Tg-rg-IP1717-Ab-2;
GM-Tg-mg-IP1717-Ab-1/ GM-Tg-mg-IP1717-Ab-2; GM-Tg-cynog-IP1717-Ab-1/ GM-Tg-cynog-IP1717-Ab-2;
GM-Tg-felg-IP1717-Ab-1/ GM-Tg-felg-IP1717-Ab-2; GM-Tg-cang-IP1717-Ab-1/ GM-Tg-cang-IP1717-Ab-2;
GM-Tg-bovg-IP1717-Ab-1/ GM-Tg-bovg-IP1717-Ab-2; GM-Tg-equg-IP1717-Ab-1/ GM-Tg-equg-IP1717-Ab-2
Products NameAnti-SLC35E4 monoclonal antibody
Formatmab
Target NameSLC35E4
Protein Sub-locationIntrocelluar Protein
Category of antibody
Derivation (species)Mouse
CH1+2+3 Isotype
(Receptor identification)		IgG
Type of Light Chain (VD-LC)N/A
Expression platformMammalian Expression
Bioactivity validationBinding affinity is validated by ELISA with recombinant soluble protein antigen. The potency in neutralizing, inhibiting or blocking of the target protein is not detected.
TagFc
Products descriptionPre-made anti-SLC35E4 monoclonal antibody(mab) is expressed by mammalian cell line as a benchmark antibody for cell culture, ELISA or other affinity binding assay or functional assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic)
Purity Purity: ≥95% (SDS-PAGE)
Application Biological drug disovery including cell culture, assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic) and mechanism of action (MOA) research.
Formulation & Reconstitution Lyophilized from GM's Protein Stability Buffer2 (PSB2,Confidential Ingredients) or PBS (pH7.4);
For PSB2, reconstituted with 0.9% sodium chloride;
For PBS, reconstituted with ddH2O.
Storage Store at -20℃ to -80℃ under sterile conditions. Avoid repeated freeze-thaw cycles.

Reference




    Data / case study


    Click to get more Data / Case study about the product.



    Associated products


    CategoryCat No.Products Name
    Target AntigenGM-Tg-g-IP1717-Ag-1Recombinant multi-species S35E4/ SLC35E4 protein


    Target information

    Target IDGM-IP1717
    Target NameSLC35E4
    Gene ID339665,103710,266687,716119,486356,101093551,523783,100063573
    Gene Symbol and SynonymsA330108F03Rik,SLC35E4
    Uniprot AccessionQ6ICL7,Q5RKL7
    Uniprot Entry NameS35E4_HUMAN,S35E4_RAT
    Protein Sub-locationIntrocelluar Protein
    Category
    DiseaseN/A
    Gene EnsemblENSG00000100036
    Target ClassificationN/A

    The target: SLC35E4, gene name: SLC35E4, also named as . Predicted to enable antiporter activity. Predicted to be involved in transmembrane transport. Predicted to be integral component of membrane. Predicted to be active in Golgi apparatus. [provided by Alliance of Genome Resources, Apr 2022].



    About Gmab

    GDU
    GDU



    GMab, developed by GeneMedi, constitutes an advanced library of recombinant monoclonal antibodies, each meticulously designed to target specific molecular entities. Leveraging the sophisticated capabilities of GM’s Taurus™ and LIBRA™ platforms, GMab synthesizes antibodies characterized by high binding affinity, exceptional physicochemical stability, and optimal developability profiles.

    Through expression in mammalian cell lines, GMab has been established as a paradigmatic reference antibody. It holds significance in myriad domains of biological drug discovery, encompassing cellular cultivation, innovative assay methodologies, strategic animal model systematization, in-depth pharmacokinetic & pharmacodynamic (PK/PD) modeling, and intricate mechanism of action (MOA) investigations.